IR BIOSCIENCES HOLDINGS INC. Inactive Instrument
IR Biosciences Holdings Inc. Stock Other OTC
Equities
IRBS
US46264M3034
Biotechnology & Medical Research
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2009 | - | Sales 2010 | - | Capitalization | 1.2M 1.64M |
|---|---|---|---|---|---|
| Net income 2009 | -6M -8.21M | Net income 2010 | -5M -6.84M | EV / Sales 2009 | - |
| Net Debt 2009 | 5.81M 7.95M | Net Debt 2010 | 3.67M 5.02M | EV / Sales 2010 | - |
| P/E ratio 2009 |
-0.37
x | P/E ratio 2010 |
-0.2
x | Employees | - |
| Yield 2009 * |
-
| Yield 2010 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 03-06-30 | |
John N. Fermanis
DFI | Director of Finance/CFO | 70 | 04-11-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 03-06-30 |
IR BioSciences Holdings, Inc. is a development-stage biotechnology company. The Company, through its wholly owned subsidiary, ImmuneRegen BioSciences, Inc. (ImmuneRegen), is engaged in the research and development of the drug candidate Homspera for use in therapies in pulmonology, immunology and hematology. The Company focuses on the research and development of therapies in the areas of pulmonary fibrosis, influenza infection and radiation-induced Neutropenia. Other areas of research include vaccine adjuvant activity evinced against certain forms of cancer and applications for wound healing and for regenerating or strengthening the human immune system, in part, through stimulating human adult stem cells.
| 1st Jan change | Capi. | |
|---|---|---|
| +25.69% | 47.9B | |
| +47.30% | 41.42B | |
| -3.46% | 40.7B | |
| -6.20% | 28.92B | |
| +9.17% | 25.55B | |
| -20.42% | 19.27B | |
| +0.17% | 12.15B | |
| +28.07% | 12.14B | |
| -1.24% | 11.99B |
